scholarly journals Breast cancer survivors in the United States

Cancer ◽  
2009 ◽  
Vol 115 (9) ◽  
pp. 1954-1966 ◽  
Author(s):  
Roberta De Angelis ◽  
Andrea Tavilla ◽  
Arduino Verdecchia ◽  
Steve Scoppa ◽  
Mark Hachey ◽  
...  
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
The United States

Assessment of genetic predisposition to lymphedema.

2011 ◽  
Vol 29 (27_suppl) ◽  
pp. 195-195
Author(s):  
J. M. Armer ◽  
B. R. Stewart
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Cancer Survivors ◽  
Cancer Treatment ◽  
Genetic Predisposition ◽  
Breast Cancer Survivors ◽  
The United States ◽  
Common Genetic Variants ◽  
Buccal Swabs ◽  
Long Term Treatment

195 Background: In the United States, 203,000 women are diagnosed annually with breast cancer (BC). Currently, over 2.3 million women in the United States are breast cancer survivors. With the increased incidence and survivorship, more women are living with the long-term treatment effects such as lymphedema (LE). We are nearing completion of stage one of a three-stage research project to examine genetic factors that potentially predispose BC survivors to develop LE. In stage one, we are working to identify novel genetic polymorphisms pointing to genomic regions and genes associated with LE risk. In stage two, we will use exome sequencing to examine both rare and common genetic variants potentially associated with variation in symptom manifestations of LE in breast cancer survivors; to examine phenotypic and genotypic variation in LE emerging following cancer treatment; and to examine associations between LE phenotypes among breast cancer survivors with LE and genomic factors and non-genomic factors. In stage three, we will replicate at the genetic level the associations detected. Methods: Institutional funding was obtained for a GWAS-design feasibility study with 96 breast cancer survivors with and without LE (48/48). Genetic material (from buccal swabs), limb volume (by perometry and circumferences), and self-reported LE-related symptoms were collected in one laboratory appointment. Results: Ninety-five percent of survivors participating in an on-going longitudinal study consented to participate in the genetic pilot (N=96). Buccal swabs provided yield for DNA extraction (concentration average 174.94 ng/ul). An additional 96 specimens have been collected for a second pilot GWAS (N =192). Conclusions: The pilot findings form the basis for a larger multisite proposed study to examine genetic predisposition to secondary LE. The findings of the larger study will lead to the design and timing of subsequent interventions aimed at reducing LE risk and improving overall survivorship quality of life. Findings concerning interactions among best cancer treatments and LE genetic predisposition will have the potential to guide the selection of cancer treatment to minimize complications when survival outcomes are equivalent across competing treatment approaches.

Health maintenance and screening in breast cancer survivors in the United States

2006 ◽  
Vol 30 (1) ◽  
pp. 52-57 ◽  
Author(s):  
Christine M. Duffy ◽  
Melissa A. Clark ◽  
Jenifer E. Allsworth
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
The United States ◽  
Health Maintenance

scholarly journals Priorities in the Cardiovascular Care of Breast Cancer Survivors

2018 ◽  
Vol 14 (4) ◽  
pp. 205-211 ◽  
Author(s):  
Bonnie Ky
Keyword(s):  
Breast Cancer ◽  
Cardiovascular Disease ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Multidisciplinary Care ◽  
The United States ◽  
Cancer Therapies ◽  
Clinical Prediction ◽  
Cardiovascular Care ◽  
Common Malignancy

Breast cancer is the most common malignancy in women with more than 3 million breast cancer survivors in the United States alone. Survivors of breast cancer suffer from an increased burden of cardiovascular risk factors and disease. The focus of this review is to describe the epidemiology of cardiovascular disease in breast cancer survivors, including the cardiovascular concerns observed with common cancer therapies. Strategies to improve upon the early detection and treatment of cardiovascular disease, including clinical prediction algorithms, biomarkers, and imaging measures are also reviewed, and the use of cardioprotective therapies to mitigate risk are summarized. Finally, the need for evidence-based research to inform and improve upon the multidisciplinary care of this growing population is highlighted.

Mammography Surveillance and Mortality in Older Breast Cancer Survivors

2007 ◽  
Vol 25 (21) ◽  
pp. 3001-3006 ◽  
Author(s):  
Timothy L. Lash ◽  
Matthew P. Fox ◽  
Diana S.M. Buist ◽  
Feifei Wei ◽  
Terry S. Field ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Cancer Mortality ◽  
Breast Cancer Survivors ◽  
Care Delivery ◽  
Breast Cancer Mortality ◽  
The United States ◽  
Stage I ◽  
Early Stage Disease

Purpose There are more than 2,000,000 breast cancer survivors in the United States today. While surveillance for asymptomatic recurrence and second primary is included in consensus recommendations, the effectiveness of this surveillance has not been well characterized. Our purpose is to estimate the effectiveness of surveillance mammography in a cohort of breast cancer survivors with complete ascertainment of surveillance mammograms and negligible losses to follow-up. Patients and Methods We enrolled 1,846 stage I and II breast cancer patients who were at least 65 years old at six integrated health care delivery systems. We used medical record review and existing databases to ascertain patient, tumor, and therapy characteristics, as well as receipt of surveillance mammograms. We linked personal identifiers to the National Death Index to ascertain date and cause of death. We matched four controls to each breast cancer decedent to estimate the association between receipt of surveillance mammogram and breast cancer mortality. Results One hundred seventy-eight women died of breast cancer during 5 years of follow-up. Each additional surveillance mammogram was associated with a 0.69-fold decrease in the odds of breast cancer mortality (95% CI, 0.52 to 0.92). The protective association was strongest among women with stage I disease, those who received mastectomy, and those in the oldest age group. Conclusion Given existing recommendations for post-therapy surveillance, trials to compare surveillance with no surveillance are unlikely. This large observational study provides support for the recommendations, suggesting that receipt of surveillance mammograms reduces the rate of breast cancer mortality in older patients diagnosed with early-stage disease.

Issues in Breast Cancer Survivorship: Optimal Care, Bone Health, and Lifestyle Modifications

2016 ◽  
pp. e22-e29
Author(s):  
Michelle E. Melisko ◽  
William J. Gradishar ◽  
Beverly Moy
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Bone Health ◽  
Breast Cancer Survivors ◽  
Care Delivery ◽  
Large Population ◽  
The United States ◽  
Breast Cancers ◽  
Lifestyle Modifications ◽  
Increased Risk

There are an estimated 3.1 million survivors of breast cancer in the United States. The predominant reasons for this substantially large population are that breast cancer is the most common noncutaneous malignancy among women and that 5-year survival rates after breast cancer treatment are approximately 90%. These patients have many medical considerations, including the need to monitor for disease recurrence and to manage complications of their previous cancer treatments. Most patients remain at risk indefinitely for local and systemic recurrences of their breast cancers and have an increased risk of developing contralateral new primary breast cancers. Therefore, optimizing care for this patient population is critical to the overall health care landscape in the United States. Here, we summarize survivorship care delivery and its challenges, the optimization of bone health in breast cancer survivors, and opportunities for risk reduction through lifestyle modifications.

Life After Cancer Epidemiology (LACE) Study: A cohort of early stage breast cancer survivors (United States)

2005 ◽  
Vol 16 (5) ◽  
pp. 545-556 ◽  
Author(s):  
Bette Caan ◽  
Barbara Sternfeld ◽  
Erica Gunderson ◽  
Ashley Coates ◽  
Charles Quesenberry ◽  
...  
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Early Stage ◽  
Cancer Epidemiology ◽  
Early Stage Breast Cancer ◽  
After Cancer

Implementing a Survivorship Care Plan for Patients With Breast Cancer

2008 ◽  
Vol 26 (5) ◽  
pp. 759-767 ◽  
Author(s):  
Patricia A. Ganz ◽  
Erin E. Hahn
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Cancer Treatment ◽  
Late Effects ◽  
Breast Cancer Survivors ◽  
The United States ◽  
Care Plan ◽  
Survivorship Care Plan ◽  
Survivorship Care ◽  
Treatment Summary

Breast cancer survivors account for 23% of the more than 10 million cancer survivors in the United States today. The treatments for breast cancer are complex and extend over a long period of time. The post-treatment period is characterized by gradual recovery from many adverse effects from treatment; however, many symptoms and problems persist as late effects (eg, infertility, menopausal symptoms, fatigue), and there may be less frequent long-term effects (eg, second cancers, lymphedema, osteoporosis). There is increasing recognition of the need to summarize the patient's course of treatment into a formal document, called the cancer treatment summary, that also includes recommendations for subsequent cancer surveillance, management of late effects, and strategies for health promotion. This article provides guidance on how oncologists can implement a cancer treatment summary and survivorship care plan for breast cancer survivors, with examples and linkage to useful resources. Providing the breast cancer treatment summary and survivorship care plan is being recognized as a key component of coordination of care that will foster the delivery of high-quality cancer care.

scholarly journals Risk of Cardiovascular Diseases Among Older Breast Cancer Survivors in the United States: A Matched Cohort Study

2021 ◽  
Vol 19 (3) ◽  
pp. 275-284
Author(s):  
Anthony A. Matthews ◽  
Sharon Peacock Hinton ◽  
Susannah Stanway ◽  
Alexander R. Lyon ◽  
Liam Smeeth ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Heart Failure ◽  
Deep Vein Thrombosis ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
The United States ◽  
Cardiovascular Outcomes ◽  
Vein Thrombosis ◽  
Deep Vein

Background: It has been suggested that cardiovascular risks are increased in breast cancer survivors, but few studies have quantified the risks of a range of specific clinically important cardiovascular outcomes in detail. Patients and Methods: Women aged >65 years with incident breast cancer from 2004 to 2013 in the SEER-Medicare linked database were matched with 5 cancer-free female counterparts (5:1 ratio). Prevalence of specific cardiovascular outcomes at baseline was measured, then Cox regression was used to calculate hazard ratios (HRs) and 95% confidence intervals for the risk of individual cardiovascular outcomes during follow-up. Modification of the effect was investigated by time since diagnosis, race/ethnicity, prior cardiovascular disease (CVD), and age. Results: In all, 91,473 women with breast cancer and 454,197 without breast cancer were included. Women with breast cancer had lower baseline prevalence of all CVDs. Compared with cancer-free controls, breast cancer survivors had substantially increased risks of deep vein thrombosis (adjusted HR, 1.67; 95% CI, 1.62–1.73; 386,484 person-years of follow-up) and pericarditis (HR, 1.43; 95% CI, 1.38–1.49; 390,776 person-years of follow-up); evidence of smaller increased risks of sudden cardiac arrest, arrhythmia, heart failure, and valvular heart disease (adjusted HRs ranging from 1.05–1.09, lower CI limits all ≥1); and evidence of lower risk of incident angina, myocardial infarction, revascularization, peripheral vascular disease, and stroke (adjusted HRs ranging from 0.89–0.98, upper CI limits all ≤1). Increased risks of arrhythmia, heart failure, pericarditis, and deep vein thrombosis persisted >5 years after cancer diagnosis. Conclusions: Women with a history of breast cancer were at increased risk of several CVDs, persisting into survivorship. Monitoring and managing cardiovascular risk throughout the long-term follow-up of women diagnosed with breast cancer should be a priority.

Sign in / Sign up

Export Citation Format

Share Document